

Revolutionizing the Next Generation Medicine through Innovative Bioavailability and Bioequivalence Approaches

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R & D Summit, September 29 – October 01, 2014 in Baltimore, USA

LOS ANGELES, CA, USA, August 14, 2013 /EINPresswire.com/ -- Bioavailability and Bioequivalence research envisions a crucial role in determining the clinical safety, efficacy outcome values which predominantly have a say in the interdependent pharmaceutical industries, regulatory agencies, patients and new drug development procedures. Acknowledging this inevitable demand for Bioavailability and Bioequivalence studies in this globalised era, OMICS Group Conferences takes the privilege to organize 5th World Congress on **Bioavailability and Bioequivalence** Pharmaceutical R & D Summit during September 29 - October 01, 2014 Baltimore, USA

<page-header><image><image><section-header><section-header><text><text><text>

5th World Congress on Bioavailability and Bioequivalence: Pharmaceutical R&D Summit 2014

The 5th World Congress on Bioavailability and

Bioequivalence revolves around the theme 'Innovative Approaches of BA/BE to Revolutionize Next Generation Medicine', opening the doors for researchers, pharmaceutical industry experts, regulatory authorities and CRO's to discuss and debate over far-reaching topics which would be paramount for the well being of humanity.

BABE-2014 promises wide ranging opportunities for sponsors, students, media partners through collaborating, interacting and promoting their products and services. A lens through the previous conferences would say it all. OMICS Group has been successfully hosting the World Congress on Bioavailability and Bioequivalence.

Under the supervision of Organizing Committee Members:

1. Sinerik Ayrapetyan - President of UNESCO Chair-LSIPEC

2. Wolfgang Sadee - Felts Mercer Professor of Medicine and Chair, The Ohio State University, USA

- 3. Lakshmi Putcha Senior Pharmacologist NASA Johnson Space Center, USA
- 4. Sean Zhang President Sino American Pharmaceutical Professionals Association, USA
- 5. Mirko Diksic Professor Emeritus, McGill University, USA
- 6. Shivanand Puthli Tris Pharma Inc., USA

Major Tracks at the conference includes:

- Emerging Bioavailability and Bioequivalence Studies
- Bioanalytical Methodology
- Contemporary Challenges of Drug Design, Discovery and Development
- Regulatory Policies, Procedures and Prerequisites for Clinical Research
- Managing BA/BE Studies
- Relevance of Genetics to BA/BE in Drug Development
- Bioavailability, Bioequivalence and Drug Product Selection
- Advances in Assessment of Bioequivalence
- Need for Conducting BA/BE Studies
- Metabolic Pathways and Changes in Nutrient Bioavailability
- Clinical Pharmacokinetics
- Clinical Pharmacology and Therapeutics
- Translational Research & Drug Discovery Biology
- Chronopharmaceutics: Germane Approach to Drug Delivery

OMICS Group also aims at delivering unlimited B2B opportunities for making business deals, product enhancements, cutting edge solutions for improving and elevating company's business and partnership with an insight to unite all the leading industry professionals, business development executives, institutional investors, capitalists and corporate investors. This enables in arranging private One-to-One meetings with other elite business representatives thereby providing access to global business community.

For more details on BABE-2014 conference, please visit: <u>http://babe2014.pharmaceuticalconferences.com/</u>

For further details contact John Benson BABE-2014 Organizing Committee <u>Pharmaceutical Conferences</u> 5716 Corsa Ave, Suite110 Westlake, Los Angeles CA-91362-7354, USA Office Ph: +1-888-843-8169 Toll Free: +1-800-216-6499(USA & Canada) E-mail: babe2014@omicsonline.net, babe2014@pharmaceuticalconferences.com, babe2014@omicsonline.us

John Benson OMICS Group Incorporation +1-888-843-8169 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/163146945

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.